Opinion|Videos|May 13, 2025
The Role of Novel Targeted Therapies
Author(s)Kathleen Moore, MD, MS
A panelist discusses how novel targeted therapies such as antibody-drug conjugates are rapidly evolving in gynecologic oncology, with multiple agents targeting different biomarkers in development, though optimal sequencing strategies remain to be determined.
Advertisement
Episodes in this series
Video content is prompted by the following:
Novel Targeted Therapies in the Treatment Landscape
Key Themes:
- Emergence of antibody-drug conjugates (ADCs) targeting various receptors
- Movement of ADCs into earlier treatment settings
- Biomarker-directed therapy approach
Notable Insights:
- Multiple ADCs are in development with different targeting mechanisms and payloads:
- Mirvetuximab soravtansine (folate receptor alpha, microtubule toxin)
- Renatabart cecitakin (folate receptor alpha, exatecan payload)
- Trastuzumab deruxtecan (HER2, deruxtecan payload)
- Relutagimod deruxtecan (cadherin-6, deruxtecan payload)
- TORL-1-23 (claudin-6, MMAE payload)
- ADCs are moving from platinum-resistant settings into maintenance therapy and frontline treatment:
- GLORIOSA trial: mirvetuximab plus bevacizumab maintenance after second-line platinum
- Trastuzumab deruxtecan trials in HRD-negative frontline maintenance
- Dr Moore emphasized that these are “very effective medications” but acknowledged: “We’re excited, but there’s a lot we have to learn...there’s just going to be quite a bit of work to do in the next years to really sort this out, to optimize for patients.”
Advertisement
Related to this article
Antimicrobial resistance in bronchiectasis and cystic fibrosis varied widely in a study spanning 11 centers on 3 continents.
Experts break down the GOLD 2026 COPD guidelines, highlighting updates to diagnosis criteria, Group E risk categories, and nonpharmacologic interventions.
An economic evaluation found nontargeted hepatitis C screening in emergency departments offered the greatest health benefit at a cost-effective price.
Naim Alkhouri, MD, on when to judge MASH treatment response, counseling on weight and muscle loss, primary care screening, and future trial end points.
Pharmacists outline new oncologic therapeutics, from pancreatic cancer to myeloma, and what high prices and crowded markets mean for payers.
Invivyd presented preclinical IDWeek 2026 data on VMS063, an investigational antibody that neutralized B3 and D8 measles variants in vitro.
Sphingolipid profiles in plasma and breath condensate differed between IPF and f-HP and tracked with disease severity, CHEST 2026 data show.
The FDA granted accelerated approval to the first plasmid DNA-based immunotherapy for adults with recurrent respiratory papillomatosis (RRP).
Advertisement
Advertisement
Trending on AJMC
1
NYC Marathon Death Puts Rhabdomyolysis Risk Factors in Focus
2
Acoramidis Linked to Fewer Hospitalizations Than Tafamidis in ATTR-CM
3
Real-World Evidence, Rare Liver Disease Data Headline Kidney Week 2026
4
EEOC Reportedly Plans to Narrow Pregnancy Accommodation Rules
5